医学临床研究
  2025年6月16日 星期一           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2018, Vol. 35 Issue (11): 2097-2100    DOI: 10.3969/j.issn.1671-7171.2018.11.006
  论 著 本期目录 | 过刊浏览 | 高级检索 |
紫杉醇辅助卡铂化疗方案治疗上皮性卵巢癌的疗效观察
李程亮, 辛宏**, 王敏娟, 石穎鹏
西安医学院第一附属医院全科医学科,陕西 西安 710077
Clinical Study on Taxol Combined with Carboplatin in Treating Epithelial Ovarian Cancer
LI Cheng-liang, XIN Hong, WANG Min-juan,et al
General Medicine Department, Xi'an Medical College First Affiliated Hospital, Shaanxi Xi'an 710077
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨紫杉醇联合卡铂化疗方案治疗上皮性卵巢癌的临床疗效。【方法】选择2015年8月至2017年7月本院诊治的上皮性卵巢癌患者80例,按随机数表法分成观察组和对照组,每组40例。观察组采用紫杉醇联合卡铂化疗,对照组单用卡铂化疗,3周为1个疗程,连续治疗2个疗程。比较两组近期疗效、不良反应发生率及化疗前后肿瘤标志物[糖类抗原(CA)199、CA125、CA153、癌胚抗原(CEA)]、免疫功能指标[CD3+ T细胞和CD4+、CD8+T细胞比例及其比值(CD4+/CD8+)]、Karnofsky行为状态量表(KPS)评分。【结果】观察组有效率为82.50%(33/40),显著高于对照组的57.50%(23/40)(P<0.05);观察组不良反应率为27.50%(11/40),与对照组的22.50%(9/40)比较差异无统计学意义(P>0.05)。两组化疗后血清CA199、CA125、CA153、CEA水平及外周血CD3+、CD4+比例和CD4+/CD8+值均较化疗前显著降低(P<0.05);外周血CD8+比例明显增加(P<0.05);且观察组化疗后血清CA199、CA125、CA153、CEA含量和外周血CD8+比例较对照组同期均显著降低(P<0.05),外周血CD3+、CD4+比例及CD4+/CD8+值均显著升高(P<0.05)。观察组化疗结束后3个月时KPS评分与化疗前相比显著增高(P<0.05),但对照组化疗前后比较无明显变化(P>0.05)。【结论】紫杉醇联合卡铂化疗方案治疗上皮性卵巢癌可显著下调患者血清肿瘤标志物表达水平,调节细胞免疫功能,提高患者生活质量,疗效显著,且安全性较高,值得临床推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李程亮
辛宏
王敏娟
石穎鹏
关键词 卵巢肿瘤/治疗药物疗法, 联合    
Abstract:【Objective】To explore the clinical efficacy of taxol combined with carboplatin on epithelial ovarian cancer. 【Methods】 A total of 80 patients with epithelial ovarian cancer admitted in our hospital from August 2015 to July 2017 were divided into two groups on the basis of random number table, with 40 cases in each group. The observation group was treated with the combination of taxol and carboplatin, while the control group received carboplatin only. Both groups were treated continuously for 2 courses, each lasting 2 weeks. The clinical efficacy, adverse reactions, changes of tumor markers [carbohydrate antigen (CA) 199, CA125, CA153, carcino-embryonic antigen (CEA)], and immune function indicators [CD3+T ratio, CD4+ ratio, CD8+ T ratio and CD4+/CD8+ value] as well as Karnofsky performance status (KPS) scores were compared between the two groups before and after treatment between the two groups. 【Results】The effective rate of the observation group was 82.50% (33/40),which was much higher than that of the control group 57.50% (23/40) (P<0.05). The incidence of adverse reactions of the observation group was 27.50% (11/40) and that of the control group was 22.50% (9/40). The difference in the incidence of adverse reactions between the two groups was not statistically different (P>0.05). After treatment both groups obtained significantly lower content of serum CA199, CA125, CA153, CEA and lower peripheral blood CD3+, CD4+, CD4+/CD8+ values (P<0.05). On the other hand, the proportion of CD8+ in peripheral blood was significantly increased (P<0.05). The serum levels of CA199, CA125, CA153, CEA and CD8+ in the observation group were significantly lower than those in the control group (P<0.05), and the peripheral blood CD3+, CD4+ ratio and CD4+/CD8+ values were significantly increased (P<0.05). The KPS score of the observation group 3 months after treatment was obviously higher than that before treatment (P<0.05), but there was no significant change before and after chemotherapy in the control group (P>0.05). 【Conclusion】 The combination of taxol and carboplatin in treating epithelial ovarian cancer can significantly lower the expression levels of serum tumor markers, regulate cellular immune function and improve patients' life quality, which is worthy of clinical application.
Key wordsOvarian Neoplasms/TH    Drug Therapy, Combination
收稿日期: 2018-07-11     
PACS:  R737.31  
基金资助:陕西省教育厅课题项目(编号:12JK0760)
通讯作者: E-mail:426831278@qq.com   
引用本文:   
李程亮, 辛宏, 王敏娟, 石穎鹏. 紫杉醇辅助卡铂化疗方案治疗上皮性卵巢癌的疗效观察[J]. 医学临床研究, 2018, 35(11): 2097-2100.
LI Cheng-liang, XIN Hong, WANG Min-juan,et al. Clinical Study on Taxol Combined with Carboplatin in Treating Epithelial Ovarian Cancer. JOURNAL OF CLINICAL RESEARCH, 2018, 35(11): 2097-2100.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2018.11.006     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2018/V35/I11/2097
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn